Epkinly (Epcoritamab-Bysp) Patent Expiration, LOE Window & CMS Spending

Epkinly (Epcoritamab-Bysp) by Genmab Us: Biologic BLA (Purple Book Regime), 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and $15,226 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGenmab Us
FDA Application & PathwayB761324 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.8M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($15,226 intro WAC)